Llwytho...
Immunotherapy of melanoma
The immunotherapy is currently changing the landscape of oncology. Nowadays the standard of care in metastatic or unresectable melanoma patients include immunomodulating modalities such as anti-PD-1 drugs (nivolumab, pembrolizumab) and anti-CTLA-4 antibody ipilimumab. The improvements of progression...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Contemp Oncol (Pozn) |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Termedia Publishing House
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5885078/ https://ncbi.nlm.nih.gov/pubmed/29628796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2018.73889 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|